Vycor Medical Q2 revenue down 16% to $418K; operating profit falls to $6.9K

VYCOR MEDICAL INC

2026-Q2 EPS reported $0.00 revenue$876,804

Q2 2026 revenue $418,264, down 16% YoY; Vycor Medical division down 17% to $401,224 on international weakness.
Q2 operating profit $6,851 vs $51,146 in 2025; non-GAAP operating profit $22,952 vs $85,712.
Six-month revenue $876,804, down 6%; operating profit $52,659 vs $38,340 in 2025.
NovaVision in development: Q2 revenue $17,040, up 17% YoY; six-month $35,139, up 8%.
Three new peer-reviewed VBAS studies published in 2026; total now 53 peer-reviewed papers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.